NEWS

Meabco has initiated a BP-C1 Health Care Cost comparison aiming at quantifying the savings that can be achieved, without reducing the efficacy.

The simple administration of the BP-C1 anti-cancer agents combined with the reduced side effects are anticipated to reduce treatment costs a well as the follow-up (adjuvant treatment, rehabilitation, etc.) costs significantly. The results of study, which is undertaken by independent consultants, will be available in the first part of 2007.